Almirall(OTC) LBTSF

Market Cap$3.34B

Since IPO (2011)+76%

5 Year+7%

1 Year+70%

1 Month+0%

$15.35

+0.00%

+0.00Today

Almirall last closing stock price
Metric	Price	Date
Last close	USD 15.35	2026-06-12

Almirall stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 15.35	2026-02-09
1 month	+0%	USD 15.35	2026-02-09
3 month	+0%	USD 15.35	2026-02-09
Year to date	-0.78%	USD 15.47	2025-12-12
1 year	+70.37%	USD 9.01	2025-06-11
3 year	+58.57%	USD 9.68	2023-06-09
5 year	+6.69%	USD 14.39	2021-05-10
Since inception	+75.74%	USD 8.73	2011-08-16

Almirall Financials at a Glance

Market Cap

$3.34B

Revenue (TTM)

€1.41B

Net Income (TTM)

€71.72M

EPS (TTM)

$0.32

P/E Ratio

48.03

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$15.35

Volume

Open

$15.35

Price

$15.35

Volume

Open

$15.35

Previous Close

$15.35

Daily Range

$15.35 - $15.35

52-Week Range

$13.36 - $15.47

Estimated Earnings Date

Nov 9, 2026

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$15.35

Volume

Open

$15.35

Previous Close

$15.35

Daily Range

$15.35 - $15.35

52-Week Range

$13.36 - $15.47

Estimated Earnings Date

Nov 9, 2026

LBTSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Almirall

Almirall, S.A. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals. The company operates across Europe, the United States, and various international markets, providing treatments for a wide range of skin conditions.

Products and Services

Specializes in dermatology treatments for conditions like psoriasis and acne
Offers products such as Ilumetri, Solaraze, and Actikerall
Extends offerings to cardiovascular, respiratory, and neurological disorders

Growth Outlook

Revenue of €314 million in Q2 2026, showing strong market demand
Trailing twelve months (TTM) revenue growth indicates robust operational performance
Strategic collaborations enhance product pipeline and market reach

Financial Highlights

Net income of €24 million in Q2 2026, reflecting effective cost management
TTM gross profit margin of 47.5%, indicating strong profitability
Current ratio of 2.32, showcasing solid liquidity position

Almirall, S.A. has established itself as a key player in the biopharmaceutical industry, particularly in dermatology. The company's diverse product portfolio and strategic partnerships position it well for future growth. Recent financial performance highlights, including a significant revenue increase and strong net income, underscore the company's operational efficiency and market potential. With a focus on innovation and expanding therapeutic areas, Almirall is poised to capitalize on emerging opportunities in the healthcare sector.

AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,097

CEO

Carlos Gallardo Piqué, MBA

Website

www.almirall.com

Headquarters

Barcelona, 08022, ES

LBTSF Financials

Key Financial Metrics (TTM)

Gross Margin

74.04%

Operating Margin

8.50%

Net Income Margin

5.09%

Return on Equity

4.78%

Return on Capital

3.70%

Return on Assets

3.03%

Earnings Yield

2.08%

Dividend Yield

0.00%

Payout Ratio

5.29%

Stock Overview

Market Cap

$3.34B

Shares Outstanding

217.78M

Volume

Avg. Volume

0.111

Financials (TTM)

Gross Profit

€1.45B

Operating Income

€580.80M

EBITDA

€485.85M

Operating Cash Flow

€333.85M

Capital Expenditure

-€125.85M

Free Cash Flow

€238.89M

Cash & ST Invst.

€355.41M

Total Debt

€356.11M

Almirall Performance Analysis

Almirall annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 907,251,477	-7.2%
2023	2023-12-31	EUR 967,075,205	6.6%
2024	2024-12-31	EUR 1,066,245,294	10.3%
2025	2025-12-31	EUR 1,250,559,170	17.3%

Almirall sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-5.1%
Q4	2025-12-31	110.4%
Q1	2026-03-31	-46.7%
Q2	2026-06-30	6.2%

Almirall annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 0.02	N/A
2023	2023-12-31	EUR -0.21	N/A
2024	2024-12-31	EUR 0.05	N/A
2025	2025-12-31	EUR 0.24	369.0%

Almirall sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	151.9%
Q4	2025-12-31	53.3%
Q1	2026-03-31	-20.6%
Q2	2026-06-30	53.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€310.32M

+13.1%

Gross Profit

€574.44M

+129.9%

Gross Margin

1.85%

N/A

Market Cap

$3.34B

N/A

Market Cap/Employee

$1.65M

N/A

Employees

2,026

N/A

Net Income

€24.26M

+387.3%

EBITDA

€80.45M

+49.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€355.41M

+10.0%

Total Debt

€356.11M

-12.0%

Accounts Receivable

€195.86M

+16.0%

Inventory

€173.45M

-3.5%

Long Term Debt

€338.09M

-12.4%

Short Term Debt

€18.02M

-3.4%

Return on Assets

3.03%

N/A

Return on Invested Capital

5.86%

N/A

Free Cash Flow

€5.04M

+112.3%

Operating Cash Flow

€83.93M

+169.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CURLFCuraleaf Holdings, Inc.

CURLFCuraleaf Holdings, Inc.$9.28+0.65%

HTSUFHisamitsu Pharmaceutical Co., Inc.

HTSUFHisamitsu Pharmaceutical Co., Inc.$29.00+0.00%

GTBIFGreen Thumb Industries Inc.

GTBIFGreen Thumb Industries Inc.$6.89+0.29%

VTRLYVitrolife AB (publ)

VTRLYVitrolife AB (publ)$9.50+0.00%

CASBFCanSino Biologics Inc.

CASBFCanSino Biologics Inc.$3.15+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$133.11+0.16%

TTDThe Trade Desk

TTDThe Trade Desk$13.80-0.22%

NVDANvidia

NVDANvidia$223.96+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.76+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.11+0.06%

PLTRPalantir Technologies

PLTRPalantir Technologies$172.01+0.10%

INTCIntel

INTCIntel$101.65+0.02%

Questions About LBTSF

What is the current price of Almirall?

Almirall is trading at $15.35 per share.

What is the 52-week range for Almirall?

Over the past 52 weeks, Almirall has traded between $13.36 and $15.47.

How much debt does Almirall have?

As of the most recent reporting period, Almirall reported total debt of €367.40M.

How much cash does Almirall have on hand?

Almirall reported €405.38M in cash and cash equivalents in its most recent financial results.

What is Almirall’s dividend yield?

Almirall does not currently have a dividend yield.

Almirall(OTC) LBTSF

Almirall Financials at a Glance

LBTSF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Almirall

LBTSF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Almirall Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LBTSF

What is the current price of Almirall?

What is the 52-week range for Almirall?

How much debt does Almirall have?

How much cash does Almirall have on hand?

What is Almirall’s dividend yield?

Premium Investing Services